Investor Presentation- Q4 FY26
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Lupin reported strong Q4 FY26 results with sales of ₹73,919 million (33% YoY growth), EBITDA of ₹21,711 million (29.4% margin), and net income of ₹14,604 million (89% YoY growth). For the full year FY26, sales reached ₹274,875 million (24% YoY) with EBITDA margins expanding to 29.7% from 23.8% in FY25. Key developments include completing the acquisition of VISUfarma B.V. in Europe, European Commission approval for biosimilar Ranibizumab (Ranluspec), and a license agreement with Galenicum for Semaglutide in 23 countries. The US business grew 46% YoY to ₹33,987 million, driven by 15 product launches in FY26. India business grew 12% YoY with the company ranked #3 in Cardiac and Respiratory segments. Management targets 100+ new product launches by FY31 with 65%+ revenue share from complex products.
Strong margin expansion and robust growth across regions signal improving operational efficiency. The strategic focus on complex generics, biosimilars, and specialty portfolio positions Lupin for sustained growth. Management's explicit margin improvement trajectory and cost optimization initiatives are positive for shareholder returns.